You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Claims for Patent: 11,167,004


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,167,004
Title:Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
Abstract:The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable.
Inventor(s):Radin Allen, Graham Neil, Akinlade Bolanle, Pirozzi Gianluca, Sun Xing, Hultsch Thomas, Shumel Brad S., Bansal Ashish
Assignee:
Application Number:US16513285
Patent Claims:

Details for Patent 11,167,004

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Regeneron Pharmaceuticals, Inc. DUPIXENT dupilumab Injection 761055 March 28, 2017 ⤷  Get Started Free 2039-07-16
Regeneron Pharmaceuticals, Inc. DUPIXENT dupilumab Injection 761055 October 19, 2018 ⤷  Get Started Free 2039-07-16
Regeneron Pharmaceuticals, Inc. DUPIXENT dupilumab Injection 761055 June 18, 2020 ⤷  Get Started Free 2039-07-16
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.